Latest news for Gold Mountain Mining (OTC:GMTNF) Stock

Gold Mountain Mining Corp is a gold and silver exploration and development company. It focuses on the expansion of the resource at the Elk Gold Project, a past-producing mine located 57 km from Merritt in South Central British Columbia. It operates in a single segment, being the production of crushed ore and mineral exploration and development of resources.

News

Penny Stocks

Offerings

GMTNF

TSX:GMTN

Gold Mountain Mining Stock Slides After Bought Deal Public Offering

GOLD MTN MNG CORP by Gold Mountain Mining Corp.

Gold Mountain Mining Corp

WIIM

Vistra Corp shares are trading higher after Morgan Stanley raised its price target on the stock from $110 to $132.

Qualcomm Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) stock has been stuck in a trading range since early August, with analysts speculating <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40981806/qualcomms-potential-intel-buyout-could-face-antitrust-hurdles-analysts-reveal-intri">about a potential bid</a> for Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). Despite this, shares have faced resistance at the top of the range, which has prompted our trading experts to make it the Stock of the Day.
As the chart below shows, the top of the range has been around $175.00.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="631" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23141002/qcom-chart-1024x631.png" alt="" class="wp-image-561717" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23141002/qcom-chart-1024x631.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23141002/qcom-chart-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23141002/qcom-chart-768x473.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23141002/qcom-chart.png 1185w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Resistance can stay intact for a long time because of buyer's remorse. Some traders and investors bought shares while the stock was at the top of the range and came to regret doing so when the price moved lower soon after.
Some thought they made a mistake and decided to sell, but they didn't want to lose money. As a result, when the shares rallied back to resistance, these remorseful buyers placed sell orders. If there is a large number of these sell orders, it will create resistance at the level once again.
Read Also: <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">Qualcomm Takeover Of Intel Is &#8216;Logically Unlikely&#8217; In Face Of Regulatory Challenges, Analyst Says</a>
The bottom of the range is around $158.00.
Support can stay intact for a long time for the opposite reason: sellers&#8217; remorse. There are traders and investors who sold shares at the bottom of the range. When the price moved higher, a number of them thought they made a mistake and decided to buy their shares back.
But they don't want to pay a higher price than they sold them for. As a result, when the price drops back to the bottom of the range, they place buy orders. If there are enough of these buy orders, it will create support at the same price that had previously been support.
If understood and applied correctly, technical analysis is the study of investor and trader psychology. These are what cause patterns to form on charts. Support can stay intact for an extended time because of seller's remorse. Resistance can stay intact for an extended period because of buyer's remorse.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40981806/qualcomms-potential-intel-buyout-could-face-antitrust-hurdles-analysts-reveal-intri">Qualcomm&#8217;s Potential Intel Buyout Could Face Antitrust Hurdles, Analysts Reveal: &#8216;Intriguing On Many Levels&#8217;</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

Trading Ideas

INTC

QCOM

Stock Of The Day: Why Qualcomm Stock Remains Stuck In A Range As Speculation Of Intel Takeover Grows

Sea shares are trading higher after B of A Securities raised its price target on stock from $84 to $96.

When Facebook parent company Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) hosts its annual developer conference this week, analysts expect the focus <a href="https://www.benzinga.com/topic/augmented-reality">to be on augmented reality</a>.
The event, scheduled for Sept. 25 and Sept. 26, has the potential for upside from <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence announcements.</a>
Meta Connect 2024: Meta Platforms is expected to highlight new products at its annual Connect developer conference and share updates on its latest <a href="https://www.benzinga.com/topic/meta-quest">virtual and augmented reality devices.</a>
Meta Connect will <a href="https://www.meta.com/connect/">stream </a>live on the company's official website for the event. Meta CEO Mark Zuckerberg will deliver the keynote address on Wednesday at 1 p.m. ET. Programming from other Meta executives will follow. 
 Owners of Meta Quest headsets can also watch the event live in Horizon Worlds.
Among the most anticipated items from the event could be a lower cots Quest 3S device with a reported $299.99 price, as <a href="https://www.theverge.com/24250169/meta-connect-2024-stream-quest-3s-vr-ar-ai">reported </a>by The Verge. Meta could also highlight its Ray-Ban Meta smart glasses.
The product highlights and price points could have Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares on high alert <a href="https://www.benzinga.com/news/24/09/40909648/snap-unveils-smart-glasses-to-bring-ar-technology-to-physical-world-what-investors-need-to-know">with competing products</a>.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/07/40081701/meta-platforms-q2-earnings-revenue-beat-eps-beat-strong-guidance-meta-ai-is-on-track-to-be-the-most">Meta Platforms Q2 Earnings: Revenue Beat, EPS Beat, Strong Guidance — &#8216;Meta AI Is On Track To Be The Most Used AI Assistant In The World&#8217;</a>
What Analysts Are Saying: The Meta Connect conference could show a shift in focus to augmented reality with hints of artificial intelligence, Bank of America analyst Justin Post said.
The analyst, who has a Buy rating and $563 price target, said the conference could highlight progress in augmented reality and artificial intelligence.
Post expects Meta to reveal a prototype of next-gen AR glasses and Meta to put a bigger focus on mixed reality and augmented reality during the presentations, instead of past focus on virtual reality.
"We expect Meta to also showcase growing AI capabilities, and the event may also include new AI product launches for core apps, announcements on Meta AI, and new AI messaging capabilities," Post said.
Meta could also launch a cheaper VR headset (Quest 3S) during the developer conference, the analyst added.
The company could also showcase third-party VR headsets from other companies building on the Horizon Worlds software platform, he added.
Post said Meta could unveil new AI functions for Messenger and WhatsApp and also give an update on large language models.
"We also think there is an opportunity for product demos showing how AI integrations across Facebook and Instagram are boosting engagement."
The analyst said there is also a small chance Meta unveils an AI subscription product during the event.
Rosenblatt analyst Barton Crockett said Meta Connect could lead the news cycle for AI for the week.
The analyst, who has a Buy rating with a $643 price target, said Meta could feature a cheaper virtual reality headset, show off new augmented reality glasses and highlight progress made in artificial intelligence integrated into existing products.
"Given Apple's sales challenges with Vision Pro, expectations for a pricey rival device from Meta have dissipated," Crockett said. "Instead, the focus is on the opposite — a cheaper version of the Meta Quest 3."
Crockett said the concern is how new products in virtual reality and augmented reality can help offset operating losses for the Reality Labs business segment.
"We struggle to see how Meta gets a positive ROIC (return on invested capital) on this. But Meta's willingness to absorb massive losses probably makes it hard for Apple and Snap to compete."
META Price Action: Meta stock trades at $566.54 on Monday versus a 52-week trading range of $279.40 to $573.98. Meta stock is up 64% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39314161/zuckerberg-targets-metas-top-brass-in-planned-job-cuts-as-his-wealth-hits-181b-stock-price-soars">Zuckerberg Targets Meta&#8217;s Top Brass In Planned Job Cuts As His Wealth Hits $181B, Stock Price Soars</a></li>
</ul>
Image: Courtesy of Meta Platforms

Analyst Color

Price Target

Reiteration

Analyst Ratings

AAPL

SNAP

Meta Connect 2024 Preview: Cheaper VR Expected, Analysts See Augmented Reality And AI As Major Focus

OneStream shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $38 price target.

Macro Notification

General

Bank Of America CEO Brian Moynihan Says US Fed Rate Cut Is A Good Start

MNSO

MINISO Group shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform.

Cabot Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cbt#NYSE">CBT</a>) recently announced that the U.S. Department of Energy&#39;s (&quot;DOE&quot;) Office of Manufacturing and Energy Supply Chains has selected it for an award negotiation for up to $50 million. This award, which is part of the Bipartisan Infrastructure Law, will help Cabot develop a new manufacturing facility in the United States to make battery-grade carbon nanotubes (CNTs) and conductive additive dispersions on a commercial scale.
These minerals are crucial to the domestic lithium-ion battery supply chain for electric cars (EVs) and the electrical grid, reducing reliance on imports. The DOE funding will cover approximately 30% of the project&#39;s entire anticipated investment of $181 million. Cabot intends to revitalize, retrofit and restore a former automotive site in Wayne County, MI, to become the United States&#39; first production facility for battery-grade CNTs and conductive additive dispersions.
Cabot has teamed up with the North American Building Trades Union, the International Chemical Workers Union Council and the Michigan Building and Construction Trades Council to support this project, which is expected to generate hundreds of new construction and full-time manufacturing jobs. This new manufacturing operation will strengthen the domestic supply chain for crucial battery ingredients, lowering dependency on foreign imports.
This investment emphasizes Cabot&#39;s role as a key participant in the energy transition, offering breakthrough material solutions not only in battery technologies but also throughout the energy storage and management ecosystem. Cabot&#39;s contributions go beyond conductive additives, including aerogels for improved thermal management, metal oxides for cathode durability and novel carbons for fuel cell optimization, all of which are critical for the next generation of sustainable energy solutions.
Shares of Cabot have gained 62% in the past year against a 1.4% decline of the industry.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4b/78742.jpg?v=1030981076" />
Image Source: Zacks Investment Research
CBT anticipates fiscal 2024 adjusted earnings per share of $7.00 to $7.10. This range represents a 30 cents increase at the midpoint, driven by the company&#39;s expectations for improved results in the Performance Chemicals segment due to higher demand and a more favorable product mix compared to the first half of the year, as well as continued strong results in the Reinforcement Materials unit.
<div class="chart_embed">
<h3>Cabot Corporation Price and Consensus</h3>
<h2><img alt="Cabot Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/99/1727087188.png" style="height:265px; width:583px" title="" /></h2>
Cabot Corporation price-consensus-chart | Cabot Corporation Quote
</div>
<h2>Zacks Rank &amp; Key Picks</h2>
CBT currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the basic materials space include Carpenter Technology Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>), Eldorado Gold Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ego#NYSE">EGO</a>) and Hawkins, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>).
Carpenter Technology currently carries a Zacks Rank #1 (Strong Buy). CRS beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 15.9%. The company&#39;s shares have soared 111.7% in the past year.
The Zacks Consensus Estimate for Eldorado&#39;s current-year earnings is pegged at $1.35 per share, indicating a year-over-year rise of 136.8%. EGO, a Zacks Rank #1 stock, beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 430.3%. The company&#39;s shares have rallied roughly 71.6% in the past year.
The Zacks Consensus Estimate for Hawkins&#39; current fiscal-year earnings is pegged at $4.14, indicating a rise of 15.3% from year-ago levels. The Zacks Consensus Estimate for HWKN&#39;s current fiscal-year earnings has increased 12.8% in the past 60 days. HWKN, a Zacks Rank #2 (Buy) stock, has rallied around 99.1% in the past year.
<a href="https://www.zacks.com/stock/news/2339654/cabot-chosen-for-50m-award-negotiation-to-aid-battery-supply-chain?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2339654">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Mid Cap

Markets

HWKN

Cabot Chosen for $50M Award Negotiation to Aid Battery Supply Chain

Whales with a lot of money to spend have taken a noticeably bullish stance on Astera Labs.
Looking at options history for Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 26% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $200,701 and 12, calls, for a total amount of $663,270.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $70.0 for Astera Labs over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Astera Labs's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Astera Labs's significant trades, within a strike price range of $35.0 to $70.0, over the past month.
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727115353_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.3</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$50.00</td>
<td>$108.0K</td>
<td style="text-align: right;">117</td>
<td style="text-align: right;">266</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$52.50</td>
<td>$93.0K</td>
<td style="text-align: right;">443</td>
<td style="text-align: right;">972</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$5.2</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$52.50</td>
<td>$87.0K</td>
<td style="text-align: right;">443</td>
<td style="text-align: right;">786</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$52.50</td>
<td>$74.5K</td>
<td style="text-align: right;">443</td>
<td style="text-align: right;">445</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$24.5</td>
<td>$23.2</td>
<td>$23.2</td>
<td>$35.00</td>
<td>$71.9K</td>
<td style="text-align: right;">149</td>
<td style="text-align: right;">31</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.
After a thorough review of the options trading surrounding Astera Labs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Astera Labs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,750,919, the ALAB's price is up by 0.48%, now at $50.75. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Astera Labs</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $55.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Overweight with a revised price target of $55. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Astera Labs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

ALAB

This Is What Whales Are Betting On Astera Labs

Financial giants have made a conspicuous bearish move on Lumen Technologies. Our analysis of options history for Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) revealed 13 unusual trades.
Delving into the details, we found 23% of traders were bullish, while 69% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $304,011, and 8 were calls, valued at $1,042,934.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $1.0 and $10.0 for Lumen Technologies, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Lumen Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lumen Technologies's whale activity within a strike price range from $1.0 to $10.0 in the last 30 days. 
<h3>Lumen Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727115348_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$7.00</td>
<td>$170.2K</td>
<td style="text-align: right;">709</td>
<td>5.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$7.00</td>
<td>$170.0K</td>
<td style="text-align: right;">709</td>
<td>2.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.69</td>
<td>$1.7</td>
<td>$7.00</td>
<td>$170.0K</td>
<td style="text-align: right;">709</td>
<td>1.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.69</td>
<td>$1.69</td>
<td>$7.00</td>
<td>$169.0K</td>
<td style="text-align: right;">709</td>
<td>5.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.68</td>
<td>$1.68</td>
<td>$7.00</td>
<td>$167.6K</td>
<td style="text-align: right;">709</td>
<td>3.0K</td>
</tr>
</tbody>
</table>

<h3>About Lumen Technologies</h3>
With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 has shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Having examined the options trading patterns of Lumen Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Lumen Technologies's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 9,235,524, the LUMN's price is up by 5.86%, now at $7.05. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 36 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lumen Technologies with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

LUMN

Spotlight on Lumen Technologies: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Morgan Stanley.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 87%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $115,490, and 6 are calls, for a total amount of $341,396.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $109.0 for Morgan Stanley over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Morgan Stanley's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Morgan Stanley's whale trades within a strike price range from $85.0 to $109.0 in the last 30 days. 
<h3>Morgan Stanley 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727115343_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.19</td>
<td>$1.06</td>
<td>$1.16</td>
<td>$107.00</td>
<td>$105.3K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.17</td>
<td>$1.17</td>
<td>$107.00</td>
<td>$81.9K</td>
<td>0</td>
<td>2.5K</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.35</td>
<td>$85.00</td>
<td>$81.7K</td>
<td>235</td>
<td>264</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.18</td>
<td>$1.18</td>
<td>$107.00</td>
<td>$52.6K</td>
<td>0</td>
<td>3.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$1.1</td>
<td>$1.08</td>
<td>$1.08</td>
<td>$102.00</td>
<td>$41.9K</td>
<td>1.9K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Morgan Stanley</h3>
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.
Following our analysis of the options activities associated with Morgan Stanley, we pivot to a closer look at the company's own performance.
<h3>Current Position of Morgan Stanley</h3>
<ul>
<li>Currently trading with a volume of 1,573,290, the MS's price is down by -0.42%, now at $102.04. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 23 days.</li>
</ul>
<h3>What Analysts Are Saying About Morgan Stanley</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $105.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral, setting a price target of $105. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Morgan Stanley with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Morgan Stanley's Options Market Dynamics

Qualcomm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) shares are experiencing a decline Monday after reports surfaced about the company&#8217;s interest in acquiring Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). Here&#8217;s <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">what you need to know</a>.
What To Know: The news highlights Qualcomm&#8217;s potential strategic move to bolster its product line and diversify its business through a multi-billion dollar acquisition of Intel. At the same time, Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has proposed a significant investment in Intel.
The Qualcomm-Intel deal, if it materializes, would mark one of the largest mergers in the semiconductor industry, potentially surpassing Microsoft&#8217;s $69 billion acquisition of Activision Blizzard. However, analysts have raised concerns about the financial and regulatory hurdles Qualcomm could face.
Recap:
<ol>
<li>Qualcomm&#8217;s Potential Acquisition of Intel: Reports indicate that Qualcomm, led by CEO Cristiano Amon, is considering acquiring Intel as part of its broader efforts to diversify. The deal would involve merging two of the world's major chipmakers, impacting sectors such as smartphones, PCs and servers. However, industry analysts believe that Qualcomm will face significant antitrust scrutiny, especially given the size and scale of both companies. </li>
<li>Apollo Global's $5 Billion Investment Offer: Separately, Apollo Global Management has proposed a $5 billion investment in Intel. Apollo and Intel already have a working relationship after Apollo's $11 billion deal earlier this year to acquire a stake in an Intel venture in Ireland. </li>
<li>Intel's Struggles and Recent Developments: Intel has been facing one of its most challenging periods in decades, with its market value dropping below $100 billion. The company reported dismal second-quarter earnings, which saw an 84% drop compared to the previous year. </li>
</ol>
QCOM Price Action: Qualcomm&#8217;s shares dropped by 1.37%, currently trading at $166.61 according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-1024x545.png" alt="" class="wp-image-561675" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40987452/assembly-biosciences-investigational-herpes-treatment-shows-antiviral-efficacy-safety-in-healthy-">Assembly Biosciences&#8217; Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants</a></li>
</ul>
Image Via Shutterstock.

Movers

Why Are QCOM Shares Moving Today?

Boeing Calls New Proposal "Best And Final Offer" To Resolve Machinists Strike

Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.
The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">Gilead Unveils &#8216;Remarkable Outcomes&#8217; From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections</a>.
The <a target="_blank" href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due" rel="noreferrer noopener">affected</a> product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.
Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.
The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.
Gilead has reported no adverse events associated with this recall to date.
Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.
Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.
In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they <a target="_blank" href="https://www.benzinga.com/general/biotech/21/12/24452924/gilead-recalls-two-lots-of-remdesivir-due-to-presence-of-glass-particulates" rel="noreferrer noopener">contained glass particulates</a>.
In the second quarter of 2024, Veklury&nbsp;sales decreased 16% year over year to $214 million, primarily due to lower rates of <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">COVID-19-related hospitalizations</a>.
Price Action: GILD stock is down 0.05% at $83.90 at last check Monday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" target="_blank" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.</li>
</ul>

Biotech

Equities

Large Cap

Health Care

GILD

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares are trading higher Monday. Here&#8217;s <a href="https://www.benzinga.com/markets/asia/24/09/40986319/chinese-stocks-defy-bidens-auto-import-ban-concerns-rally-to-4-month-highs-as-central-bank-unexpecte">what you need to know</a>.
What to Know: Alibaba&#8217;s cloud computing unit partnered with Nvidia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance autonomous driving for Chinese EV makers, including Li Auto, Great Wall Motor and ZEEKR. This partnership integrates Alibaba&#8217;s Qwen large language models (LLMs) with Nvidia&#8217;s Drive AGX Orin platform, improving in-car AI capabilities. This move may be seen as strategic, especially as China grapples with U.S. sanctions restricting access to advanced semiconductor chips, which impact both Nvidia and Alibaba.
Market Context: The People's Bank of China (PBoC) recently slashed key interest rates and injected liquidity into the banking system, boosting investor confidence and contributing to a broader rally in Chinese stocks. The rate cuts are part of efforts to stimulate China&#8217;s economy ahead of its National Day Holiday.
BABA Price Action: BABA is trading at $90.05, reflecting a 1.99% gain according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-1024x530.png" alt="" class="wp-image-561642" style="width:485px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40987155/mullen-automotives-bollinger-motors-powers-up-first-customer-ready-b4-electric-truck-rolls-off-t">Mullen Automotive&#8217;s Bollinger Motors Powers Up: First Customer-Ready B4 Electric Truck Rolls Off The Line In Michigan</a></li>
</ul>
Photo courtesy: Alibaba INC.

BABA

NVDA

Alibaba Shares Are Trading Higher: What's Going On

Orgenesis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares are trading lower by 21% to 40 cents during Monday&#8217;s session after the company announced that its Board of Directors has approved a <a href="https://www.benzinga.com/pressreleases/24/09/g40976804/orgenesis-announces-reverse-stock-split">1-for-10 reverse stock split</a>, effective at 5:00 pm ET on September 24.
Orgenesis says this move aims to meet Nasdaq&#8217;s minimum $1.00 bid price requirement. The stock will continue trading under the symbol &#8220;ORGS&#8221; on a split-adjusted basis starting September 25. 
The reverse split will reduce the number of outstanding shares from 47.7 million to approximately 4.77 million, while stockholders&#8217; ownership percentages remain unchanged. 
The company also announced that fractional shares will be paid out in cash based on the closing price on September 24.
Read Also: <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">Qualcomm Takeover Of Intel Is &#8216;Logically Unlikely&#8217; In Face Of Regulatory Challenges, Analyst Says</a>
<h2 class="wp-block-heading">Should I Sell My ORGS Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Orgenesis have decreased by 29.34% in the past year. An investor who bought shares of Orgenesis at the beginning of the year would take a loss of $0.05 per share if they sold it today. The stock has fallen 37.67% over the past month, meaning an investor who bought shares on Aug. 1 would see a capital loss of $0.33.
Orgenesis shares have an all-time high of $5.02, representing 1045.86% upside from current levels.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ORGS has a 52-week high of $1.08 and a 52-week low of $0.25.

ORGS

Why Orgenesis (ORGS) Stock Is Down 23% Today

Masimo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 8.5% loss over the past four weeks.
The sharp upsurge in Masimo&#39;s shares can be attributed to the surprising news regarding the company&#39;s newly elected Board of Directors. On Sept. 19, per a public statement issued from Politan, activist investor Quentin Koffey, and his Politan Capital Management group&#39;s proposed candidates, both won election to the two available Board seats of Masimo. This guarantees that the new independent directors now have a control of the Board. On Sept. 20, the share price of MASI surged as the investors continued to celebrate the news in a positive view that the new Board is likely to be more conscious of and responsive to the investors.
This medical technology company is expected to post quarterly earnings of $0.84 per share in its upcoming report, which represents a year-over-year change of +33.3%. Revenues are expected to be $501.93 million, up 4.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Masimo, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy).
Masimo is part of the Zacks Medical - Instruments industry. CVRx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvrx#NASDAQ">CVRX</a>), another stock in the same industry, closed the last trading session 1.5% lower at $9.11. CVRX has returned 10.9% in the past month.
For CVRx, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.45. This represents a change of -4.7% from what the company reported a year ago. CVRx currently has a Zacks Rank of #3 (Hold).
<a href="https://www.zacks.com/stock/news/2339653/masimo-masi-surges-8-7-is-this-an-indication-of-further-gains?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_3%-2339653">To read this article on Zacks.com click here.</a>

Small Cap

CVRX

MASI

Masimo Surges 8.7%: Is This an Indication of Further Gains?

Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading lower by 2.0% to $55.17 Monday afternoon. The stock is pulling back after rallying last week following the news of the Federal Reserve&#8217;s unexpected <a href="https://www.benzinga.com/markets/equities/24/09/40965372/fed-delivers-large-interest-rate-cut-in-bid-to-sustain-labor-market-stocks-gold-set-new-record-h">50-basis-point rate cut</a>.
Wells Fargo&#8217;s sensitivity to interest rate changes and investor speculation about the short-term effects on profitability has caused the stock to be volatile in recent sessions. 
What Happened: Last week&#8217;s larger-than-expected cut lowered the federal funds rate to a range of 4.75% to 5%, which was perceived as a positive development for Wells Fargo. Banks like Wells Fargo typically benefit from lower short-term borrowing costs, as they can access cheaper funding and potentially increase their net interest margins in the near term. 
Additionally, lower interest rates tend to stimulate borrowing by consumers and businesses, which could lead to increased loan demand and higher interest income for Wells Fargo. This potential for immediate growth in lending and profitability likely contributed to the stock&#8217;s initial rise, as investors anticipated a more favorable environment for the bank.
Read Also: <a href="https://www.benzinga.com/insights/options/24/09/40985016/what-the-options-market-tells-us-about-wells-fargo">What The Options Market Tells Us About Wells Fargo</a>
Furthermore, the Federal Reserve&#8217;s statement that inflation was moving sustainably toward 2% added to the market's confidence. As inflation concerns eased, the economic outlook seemed more stable, which would benefit Wells Fargo's business, as consumer and business confidence is critical for maintaining strong lending activity. 
The prospect of additional rate cuts, as indicated by the Fed's dot plot, suggested a longer period of easier monetary policy, further fueling the short-term enthusiasm for Wells Fargo stock.
What Else: Monday&#8217;s subsequent pullback could reflect a more cautious reassessment of the bank&#8217;s long-term outlook. Although lower interest rates reduce short-term borrowing costs, they also typically lead to a decline in long-term rates. This could compress Wells Fargo&#8217;s net interest margins, as the bank earns less on long-term loans while still facing lower yields on its assets. 
Over time, the bank&#8217;s ability to generate income from interest on loans could be hampered in a prolonged low-rate environment, reducing profitability. Investors likely became concerned that while the initial rate cut seemed positive, the extended path of rate reductions might hurt Wells Fargo's ability to sustain its earnings over the longer term.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a>
Additionally, the Federal Reserve's updated economic projections painted a less favorable picture for future growth. The downward revision in real GDP growth forecasts, coupled with higher unemployment projections through 2026, signaled a weakening economy. 
This raised concerns about potential loan defaults, as higher unemployment often leads to increased credit risk. Wells Fargo, which holds large portfolios of consumer and business loans, could face rising delinquencies and losses in a slower economy. 
The bank&#8217;s exposure to consumer credit, mortgages and commercial loans means that an economic downturn or a prolonged period of sluggish growth would directly impact its earnings.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
By now you're likely curious about how to participate in the market for Wells Fargo &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Wells Fargo, which is trading at $55.21 as of publishing time, $100 would buy you 1.81 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WFC has a 52-week high of $62.55 and a 52-week low of $38.38.

What's Going On With Wells Fargo (WFC) Stock?

Boeing Increases General Wage By 30%, Boosts 401(K) Match To 100% Of First 8% Of Pay, And Raises Ratification Bonus To $6,000 In IAM Labor Negotiations

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">sharp stock decline</a> after Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) mid-stage data on its obesity drug.
Andres Maldonado of H.C. Wainwright reiterated a Buy rating for Corbus with an $80 price target, highlighting that Novo's recent challenges with monlunabant, a drug targeting the same receptor as Corbus&#8217; CRB-913, should not impact the latter's potential. The stock currently trades below the $20 mark.
Maldonado<a href="https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-corbus-pharmaceuticals-on-crb-913s-potential-and-holistic-pipeline-valuation?utm_source=benzinga.com&amp;utm_medium=referral"> stressed </a>that different drugs within the same class could exhibit unique efficacy and safety profiles.&nbsp;
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Oppenheimer And Mizuho Double Down On Corbus' Pipeline</h3>
Oppenheimer also maintained a Buy rating, setting a price target of $88, focusing not only on CRB-913 but also on Corbus' broader assets, especially CRB-701.&nbsp;
Mizuho similarly recommended <a href="https://seekingalpha.com/news/4151904-mizuho-recommends-buying-corbus-following-its-drop-post-novos-obesity-data?utm_source=partner_&amp;utm_medium=referral&amp;feed_item_type=news">buying the dip</a>, viewing the recent 60% stock plunge as an overreaction.&nbsp;
The firm pointed to CRB-701's positive Phase 1 data and sees the company's valuation primarily tied to this Nectin-4-based ADC for cancer treatment, rather than the obesity drug alone.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk&#8217;s Cannabinoid-Based Weight Loss Drug Trial Disappoints</a>

Cannabis

CRBP

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Gold Mountain Mining GAAP EPS of $0.00, revenue of $105M

Press Releases

Gold Mountain Appoints Hugh Behroozy to The Board of Directors

Gold Mountain Appoints Nadine Hoehne to The Board of Directors

Star Royalties Reports Q1 2024 Financial Results

Gold Mountain Announces Further Debt Settlements and Issuance of Convertible Debenture

Gold Mountain Announces Closing of Debt Settlement Transactions and Issuance of Convertible Debenture

Gold Mountain Mining 2024 Annual General Meeting Voting Results

Gold Mountain Announces Financing of $6.5 Million by Way of Issuance of a Convertible Debenture

Star Royalties Reports Q2 2024 Financial Results

Gold Mountain Announces Closing of $6.5 Million Financing

Gold Mountain Reports its Q2 2025 Financial and Operating Results

SGLDF

STRFF

TSX:AEM

TSX:CVE

TSX:SGLD

TSX:STRR

TSXV:STRR

Gold Mountain Mining

<ul>
	<li>Gold Mountain Mining Corp&nbsp;(TSX:<a class="ticker" href="https://www.benzinga.com/stock/GMTN#TSX">GMTN</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GMTNF#OTC">GMTNF</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/04/g26621067/gold-mountain-announces-increase-in-bought-deal-public-offering-to-18-5-million" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">entered into an amended agreement</a>&nbsp;with Eight Capital, under which the Underwriters have now agreed to purchase, on a bought deal basis, 14.8 million units for C$1.25 per unit for aggregate gross proceeds of C$18.5 million.</li>
	<li>The&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/04/g26609594/gold-mountain-announces-12-0-million-bought-deal-public-offering" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">prior agreement</a>&nbsp;consisted of 9.6 million units at C$1.25 per unit for aggregate gross proceeds of C$12 million.</li>
	<li>Each Unit consists of one common share and one-half of one common share purchase warrant.</li>
	<li>Each Warrant is exercisable into one common share at an exercise price of C$1.75 for 24 months from the closing of the offering.&nbsp;</li>
	<li>The company plans to use the offering net proceeds for the development of the Elk Gold Project and working capital and general corporate purposes.</li>
	<li>The offering is scheduled to close on or about April 21, 2022.</li>
	<li>Price Action:&nbsp;GMTN shares are trading lower by 16.78% at C$1.19 on TSX, and GMTNF is lower by 16.26% at $0.95 on the last check Wednesday.</li>
</ul>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Gold Mountain Mining

News

Latest news for Gold Mountain Mining (OTC:GMTNF) Stock

Wednesday, April 13, 2022